How do you sell lefty ideas to righty politicians? What’s going on at Gilead Sciences? And why are biotech investors freaking out?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT D.C. correspondent Lev Facher joins us to talk about Health and Human Services Secretary Alex Azar’s efforts to convince conservatives that tying Medicare payments to overseas drug prices is a good idea. Then, we delve into how the federal government’s sudden scrutiny over investments from China is rattling biotech. That’s followed by quick explorations of a debate over the ethics of animal research, the scientific history of a new Amgen (AMGN) drug, and why Gilead’s latest move is inspiring more fret than relief.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy